Literature DB >> 33237483

Evaluation of the impact of age and adiposity on a multi-biomarker disease activity score before and after adjustment.

Joshua F Baker1,2,3, Jeffrey R Curtis4, David Chernoff5, Darl D Flake5, Eric Sasso5, Jin Long6, Elena Taratuta7, Michael D George8,9.   

Abstract

PURPOSE: We assessed the impact of adjustment of the multi-biomarker disease activity score (MBDA) for age, sex, and leptin, over the range of age and adiposity, and assessed relationships with clinical disease activity.
METHODS: Patients with RA, ages 18-75 years, were recruited from clinical practices and completed whole-body DXA to quantify fat mass indices (FMI, kg/m2). FMI Z-scores were calculated based on distributions in a reference population. Descriptive statistics described relationships between age, FMI Z-score, and the original MBDA and adjusted MBDA (aMBDA). Swollen joint counts (SJC) and the clinical disease activity index (CDAI) were assessed over MBDA categories.
RESULTS: There were 104 participants (50% female) with mean (SD) age of 56.1 (12.5) and body mass index (BMI) of 28.8 (6.9). Older age was associated with higher MBDA scores in men. The aMBDA was not associated with age. The original MBDA score was associated with FMI Z-score among women (Rho = 0.42, p = 0.002) but not men. The aMBDA was not associated with FMI Z-score in either women or men. The aMBDA score was lower than the original MBDA in the highest quartile of FMI in women and was higher in the lowest FMI quartiles in women and men. CDAI, SJC, and radiographic scores were similar across activity categories for the original MBDA score and aMBDA.
CONCLUSIONS: The aMBDA demonstrated reduced associations with adiposity, particularly among women. The aMBDA may be less likely to overestimate disease activity in women with greater adiposity and to underestimate disease activity in men and women with lesser adiposity. Key Points • Leptin adjustment of the MBDA score reduces the influence of adiposity, particularly among women. • Leptin adjustment results in significantly higher estimated disease activity in thin men and women. • The adjusted and unadjusted score correlate similarly with clinical disease activity measures.

Entities:  

Keywords:  Biomarkers; Disease activity; Obesity; Rheumatoid arthritis: Adiposity

Mesh:

Substances:

Year:  2020        PMID: 33237483      PMCID: PMC8127402          DOI: 10.1007/s10067-020-05508-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  10 in total

1.  Global assessments of disease activity are age-dependent determinant factors of clinical remission in rheumatoid arthritis.

Authors:  Hideki Ito; Takehisa Ogura; Ayako Hirata; Sayaka Takenaka; Kennosuke Mizushina; Yuki Fujisawa; Takaharu Katagiri; Norihide Hayashi; Hideto Kameda
Journal:  Semin Arthritis Rheum       Date:  2017-04-28       Impact factor: 5.532

2.  Association of Serum hs-CRP Levels With the Presence of Obesity, Diabetes Mellitus, and Other Cardiovascular Risk Factors.

Authors:  Mahmoud Ebrahimi; Ali Reza Heidari-Bakavoli; Sara Shoeibi; Seyed Reza Mirhafez; Mohsen Moohebati; Habibollah Esmaily; Hamed Ghazavi; Maryam Saberi Karimian; Seyed Mohammad Reza Parizadeh; Maryam Mohammadi; Hossein Mohaddes Ardabili; Gordon A Ferns; Majid Ghayour-Mobarhan
Journal:  J Clin Lab Anal       Date:  2016-02-08       Impact factor: 2.352

Review 3.  Inflammatory markers in population studies of aging.

Authors:  Tushar Singh; Anne B Newman
Journal:  Ageing Res Rev       Date:  2010-12-08       Impact factor: 10.895

4.  Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis.

Authors:  Michael D George; Mikkel Østergaard; Philip G Conaghan; Paul Emery; Daniel G Baker; Joshua F Baker
Journal:  Ann Rheum Dis       Date:  2017-06-12       Impact factor: 19.103

5.  Relation between body mass index and radiological progression in patients with rheumatoid arthritis.

Authors:  Jörg Kaufmann; Volker Kielstein; Susann Kilian; Günter Stein; Gert Hein
Journal:  J Rheumatol       Date:  2003-11       Impact factor: 4.666

6.  Attenuated age-impact on systemic inflammatory markers in the presence of a metabolic burden.

Authors:  Anuurad Erdembileg; Annie Mirsoian; Byambaa Enkhmaa; Wei Zhang; Laurel A Beckett; William J Murphy; Lars F Berglund
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

7.  Dual energy X-Ray absorptiometry body composition reference values from NHANES.

Authors:  Thomas L Kelly; Kevin E Wilson; Steven B Heymsfield
Journal:  PLoS One       Date:  2009-09-15       Impact factor: 3.240

8.  Greater body mass independently predicts less radiographic progression on X-ray and MRI over 1-2 years.

Authors:  Joshua F Baker; Mikkel Ostergaard; Michael George; Justine Shults; Paul Emery; Daniel G Baker; Philip G Conaghan
Journal:  Ann Rheum Dis       Date:  2014-08-04       Impact factor: 19.103

9.  Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.

Authors:  Karen Hambardzumyan; Rebecca Bolce; Saedis Saevarsdottir; Scott E Cruickshank; Eric H Sasso; David Chernoff; Kristina Forslind; Ingemar F Petersson; Pierre Geborek; Ronald F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2014-05-08       Impact factor: 19.103

10.  Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate.

Authors:  Josef S Smolen; Ronald F van Vollenhoven; Stefan Florentinus; Su Chen; Jessica L Suboticki; Arthur Kavanaugh
Journal:  Ann Rheum Dis       Date:  2018-08-03       Impact factor: 19.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.